

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Recbio Technology Co., Ltd.

江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2179)

**CHANGE OF THE CHAIRMAN OF THE BOARD OF DIRECTORS
AND
ADJUSTMENT TO THE COMPOSITION OF THE NOMINATION
COMMITTEE**

CHANGE OF THE CHAIRMAN OF THE BOARD OF DIRECTORS

The board of directors (the “**Board**”) of Jiangsu Recbio Technology Co., Ltd. (the “**Company**”) received a resignation letter from Dr. LIU Yong on December 22, 2025. To further enhance corporate governance level and to dedicate more time to other commitments, Dr. LIU Yong resigned from his positions as the Chairman of the Board and the Chairman of the Nomination Committee of the Board of the Company, with effect upon the election of a new Chairman by the Board. Dr. LIU Yong will continue to serve as an executive director and the General Manager of the Company, overseeing the overall production, operations, and management of the Company.

Dr. LIU Yong has confirmed that he has no disagreement with the Company and the Board, and that there are no other matters relating to his resignation that need to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) or the shareholders of the Company.

The Company hereby takes this opportunity to express its sincere gratitude to Dr. LIU Yong for his valuable contributions to the development of the Company during his tenure of office.

The Board is pleased to announce that at the Board meeting held on December 23, 2025, Mr. XU Haoyu was elected as the Chairman of the Board of the second session of the Board of the Company, with a term commencing from the date of approval by the Board until the expiry of the term of the second session of the Board.

The biographical details of Mr. XU Haoyu are set out as follows:

Mr. XU Haoyu, aged 53, is currently a representative of the 14th National People’s Congress, president of the Medical and Pharmaceutical Chamber of Commerce of China Federation of Industry and Commerce, and secretary of the Party Committee, chairman and president of Yangtze River Pharmaceutical (Group) Co., Ltd. (揚子江藥業集團有限公司).

Mr. XU Haoyu joined Yangtze River Pharmaceutical (Group) Co., Ltd. in 1994, who has more than thirty years of experience in the industry and management. From July 1994 to June 2021, Mr. XU Haoyu successively served as a staff member in the sales office, provincial company manager, deputy director and vice chairman of Yangtze River Pharmaceutical (Group) Co., Ltd. Since July 2021, he has been serving as the secretary of the Party Committee, chairman and president of Yangtze River Pharmaceutical (Group) Co., Ltd.

Guided by the strategy of Healthy China, Mr. XU Haoyu is committed to the corporate mission of “Commit for Better Dedicate for Caring All”, and has proposed the dual health strategy of “Health-based Marketing and Marketing for Health”, leading Yangtze River Pharmaceutical (Group) to focus on its principal business and become stronger. In alignment with the brand philosophy of “Health for All, All in Health”, Yangtze River Pharmaceutical (Group) adheres to a dual-drive strategy of innovation and quality, and makes efforts to specialize in its products, refine its technologies and optimize its services to accelerate the transition of its industry toward high-end, intelligent and green development. It has established a three-brand matrix consisting of “Yangtze River (揚子江)” for Western medicine, “Long Feng Tang (龍鳳堂)” for traditional Chinese medicine and “Hu You (護佑)” for comprehensive health, to actively foster a health ecosystem integrating “pharmaceuticals, medicine, nursing, food, and tourism”. In recent years, Mr. XU Haoyu has been honored as “Outstanding Builder of Socialist Cause with Chinese Characteristics (優秀中國特色社會主義事業建設者)”, “Outstanding Entrepreneur of Jiangsu Province (江蘇省優秀企業家)”, and “Most Admired Military-Supporting Figure in Jiangsu (江蘇最美擁軍人物)”.

Mr. XU Haoyu graduated from Shanghai Institute of Technology in 1994, and obtained a master’s degree in business administration from Maastricht School of Management in 2002.

As the Chairman of the Board and a non-executive director of the Company, Mr. XU Haoyu will not receive any remuneration from the Company other than reasonable compensation for specific services provided to the Company and upon completion of the necessary decision-making procedures.

As at the date of this announcement, Taizhou Xinchuanlv Enterprise Management Partnership (Limited Partnership) (泰州薪傳律企業管理合夥企業(有限合夥)) (“**Taizhou Xinchuanlv**”) holds 1,069,100 H shares of the Company and Shanghai Teci Enterprise Management Co., Ltd. (上海特慈企業管理有限責任公司) is its managing partner. Shanghai Teci Enterprise Management Co., Ltd. is held by Ms. ZHU Yuqing as to 99% and Mr. XU Haoyu as to 1% of its equity interests, respectively. Ms. ZHU Yuqing is the spouse of Mr. XU Haoyu. Therefore, Mr. XU Haoyu is deemed to be interested in the shares held by Taizhou Xinchuanlv under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”). Ms. ZHU Yuqing holds 3,161,000 H shares of the Company. Mr. XU Haoyu is also deemed to be interested in the shares held by Ms. ZHU Yuqing under the SFO. Moreover, Yangtze River (Hong Kong) Limited (“**Yangtze River HK**”) holds 12,618,500 H shares of the Company, and Yangtze River Pharmaceutical (Group) Co., Ltd. (“**Yangtze River Pharmaceutical**”) holds 143,112,702 domestic shares of the Company. Mr. XU Haoyu is the chairman of Yangtze River HK and also the chairman of Yangtze River Pharmaceutical. Mr. XU Haoyu and his family respectively beneficially control 90% of Yangtze River HK and 51% of Yangtze River Pharmaceutical. Therefore, Mr. XU Haoyu and his family are deemed to be interested in the shares held by Yangtze River HK and Yangtze River Pharmaceutical under the SFO.

Save as disclosed above, as at the date of this announcement, Mr. XU Haoyu has confirmed that: (1) he has not held any directorships in other listed companies nor any other major appointments or professional qualifications during the past three years; (2) he does not hold any position in the Company or any of its subsidiaries; (3) he has no relationship with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company or any of its subsidiaries; and (4) he does not have any interests in the shares of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, the Board is not aware of any other information in relation to the election of Mr. XU Haoyu as the Chairman that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), nor is there any other matter that needs to be brought to the attention of the shareholders of the Company.

Following the appointment of Mr. XU Haoyu, the Company has complied with the requirements under Code Provision C.2.1 of the Corporate Governance Code set out in Appendix C1 to the Listing Rules, whereby the roles of Chairman of the Board and Chief Executive Officer are separated and no longer assumed by the same individual.

ADJUSTMENT TO THE COMPOSITION OF THE NOMINATION COMMITTEE

In view of the resignation report submitted by Dr. LIU Yong, and pursuant to the Listing Rules, the Company Law of the People’s Republic of China, Code of Corporate Governance for Listed Companies, the Articles of Association of the Company and the Terms of Reference of The Nomination Committee of the Board, in order to ensure the normal and continuous operation of the Nomination Committee, at the Board meeting held on December 23, 2025, Professor GAO Feng was elected as the Chairman of the Nomination Committee of the second session of the Board, and Ms. WANG Jing was elected as a member of the Nomination Committee of the second session of the Board. The terms of office of Professor GAO Feng and Ms. WANG Jing shall commence from the date of approval by the Board and shall continue until the expiry of the term of the second session of the Board.

Following the appointment of Ms. WANG Jing, the Company has complied with Code Provision B.3.5 of the Corporate Governance Code under the Appendix C1 to the Listing Rules. The Nomination Committee of the Board has appointed directors of different genders.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Mr. XU Haoyu
Chairman

Jiangsu Province, the PRC, December 23, 2025

As at the date of this announcement, the Board comprises Mr. XU Haoyu as the Chairman of the Board and a non-executive director, Dr. LIU Yong, Mr. WEI Qifang and Ms. WANG Jing as executive directors, Dr. WANG Ruwei, Dr. ZHANG Jiabin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive directors.